Prodigiosin, a bioactive secondary metabolite produced by Serratia marcescens, is an effective proapoptotic agent against various cancer cell lines, with little or no toxicity towards normal cells. The hydrophobicity of prodigiosin limits its use for medical and biotechnological applications, these limitations, however, can be overcome by using nanoscale drug carriers, resulting in promising formulations for target delivery systems with great potential for anticancer therapy. Here we report on prodigiosin-loaded halloysite-based nanoformulation and its effects on viability of malignant and non-malignant cells. We have found that prodigiosin-loaded halloysite nanotubes inhibit human epithelial colorectal adenocarcinoma (Caco-2) and human colon carcinoma (HCT116) cells proliferative activity. After treatment of Caco-2 cells with prodigiosin-loaded halloysite nanotubes, we have observed a disorganization of the F-actin structure. Comparison of this effects on malignant (Caco-2, HCT116) and non-malignant (MSC, HSF) cells suggests the selective cytotoxic and genotoxic activity of prodigiosin-HNTs nanoformulation.

The incidence of cancer is growing every year and covers all age groups, including the working population, which makes cancer socially significant. Existing methods of treatment, despite the effectiveness of individual compounds in relation to cancer cells, are not perfect due to a number of side effects associated with high doses that physicians are forced to administer when using treatment protocols. A particularly difficult issue is the creation of effective functional containers that would have the properties of targeting certain types of cells. The solution of this problem is currently relevant, which is reflected in the growth of publications on this subject in recent years. The most promising is the use of nanotechnology in the development of bioengineered therapeutics and containers for chemotherapeutic agents. In this review, we tried to assess the trends that exist in this area of research, as well as show the wide using of some commercially available formulations based on the nano-sized vehicles.

Prodigiosin is a fascinating compound that has been gaining attention in the scientific community for its diverse range of potential applications. From its vibrant red color to its unique chemical properties, prodigiosin has captured the interest of researchers looking for innovative solutions in various fields. Prodigiosin, a red pigment produced by certain bacteria such as Serratia marcescens, has attracted interest from pharmaceutical researchers due to its promising potential in various therapeutic applications. A number of studies have demonstrated the potential of prodigiosin as an antimicrobial agent. With the rise of antibiotic resistance in the environment, prodigiosin is a promising solution to combat resistant strains and improve the effectiveness of existing antibiotic therapy. Moreover, different studies have shown that this natural pigment has anticancer properties by inhibiting the growth and proliferation of cancer cells. Prodigiosin exerts its anticancer effects by inducing apoptosis in cancer cells without causing significant damage to healthy cells. In this review, we will attempt to summarize the capabilities of prodigiosin and its prospects as a valuable tool in pharmaceutical research, and also review recent studies focusing on the various industries in which prodigiosin can be applied and the exciting possibilities it holds in the future.

Here we report the use of forskolin-modified halloysite nanotubes (HNTs) as a dopant for biopolymer porous hydrogel scaffolds to impart osteoinductive properties. Forskolin is a labdane diterpenoid isolated from the Indian Coleus plant. This small molecule is widely used as a supplement in molecular biology for cell differentiation. It has been reported in some earlier publications that forskolin can activate osteodifferentiation process by cyclic adenosine monophosphate (c-AMP) signalling activation in stem cells. In presented study it was demonstrated that forskolin release from halloysite-doped scaffolds induced the osteodifferentiation of equine mesenchymal stem cells (MSCs) in vitro without addition of any specific growth factors. The reinforcement of mechanical properties of cells and intercellular space during the osteodifferentiation was demonstrated using atomic force microscopy (AFM). These clay-doped scaffolds may find applications to accelerate the regeneration of horse bone defects by inducing the processes of osteodifferentiation of endogenous MSCs.

The therapeutic potential of prodigiosin as a hydrophobic anticancer agent can be enhanced by various approaches, one of which is the loading of PG into extracellular vesicles. Drug distribution and stability in aqueous media play a crucial role in targeting and accumulation, thereby enabling the attainment of therapeutically effective drug concentrations. Extracellular vesicles are nano-sized, cell-derived vesicles with a lipid bilayer membrane. Extracellular vesicles can be utilized as drug carriers for both water-soluble and non-water-soluble therapeutic agents. We hypothesized that microvesicles could effectively address the current challenges of prodigiosin delivery. Several different techniques have been developed for fabricating extracellular vesicles. These include microvesicles induction by cytochalasin B treatment as well as cell cultivation in serum depleted media. In our study, prodigiosin, like cytochalasin B, demonstrated efficacy in microvesicles formation based on protein quantification and Nanoparticle Tracking Analysis. In addition, Nanoparticle Tracking Analysis showed that vesicles from mesenchymal stem cells are more stable under ultrasound exposure. Microvesicles encapsulating prodigiosin, compared to unmodified naïve ones, demonstrated slightly increased zeta potentials and hydrodynamic diameters, which probably contributed to better stability. We demonstrated that ultrasonic treatment for the loading of prodigiosin does not significantly increase the proportion of prodigiosin-positive microvesicles in comparison with microvesicles induced with prodigiosin; moreover, this method cannot be considered as optimal due to its disadvantages, such as particle aggregation. Prodigiosin-induced and prodigiosin-loaded microvesicles from mesenchymal stem cells were significantly smaller and less polydisperse in size. Overall, prodigiosin encapsulated in extracellular vesicles might be more suitable for medical and clinical applications compared to pure forms of PG due to their cell membrane compatibility.

The therapeutic potential of prodigiosin as a hydrophobic anticancer agent can be enhanced by various approaches. One of which is the loading of PG into extracellular vesicles. Both, drug distribution and stability in aqueous media are important for targeting and accumulation, which, in turn, is important to achieve an effective drug concentration. Extracellular vesicles (EVs) are nano-sized, cell-derived vesicles with lipid bilayer membrane. EVs can be utilized as drug carriers for both water-soluble and non-water-soluble therapeutic agents. We hypothesized that EVs could effectively address the current challenges of prodigiosin delivery. Several different techniques have been developed for fabricating extracellular vesicles. These include EVs induction with cytochalasin B, prodigiosin and cultivation in serum depleted media (serum-free cultivation). Treatment with cytochalasin B has been shown to be effective for the generation of vesicles. Prodigiosin encapsulated extracellular vesicles (PG-EVs) compared to unmodified naïve ones demonstrated slightly higher charge and hydrodynamic dimensions. Which probably contributes to better stability. Overall, PG –EVs complexes might be more suitable for medical and clinical applications compared to pure forms of PG due to their cell membrane compatibility.